Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

1.68
-0.0600-3.45%
Post-market: 1.720.0400+2.38%19:32 EDT
Volume:97.06K
Turnover:164.66K
Market Cap:2.50M
PE:-0.01
High:1.75
Open:1.75
Low:1.61
Close:1.74
52wk High:524.00
52wk Low:1.43
Shares:1.49M
Float Shares:1.48M
Volume Ratio:0.44
T/O Rate:6.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-175.9200
EPS(LYR):-303.4772
ROE:-114.61%
ROA:-51.35%
PB:0.22
PE(LYR):-0.01

Loading ...

Clearmind Medicine - no Serious Adverse Events Observed in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Announces Positive Safety Findings for Cmnd 100, Demonstrating Consistent Tolerability Throughout Full Dose Escalation in Part a of Its FDA-Regulated Clinical Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine - All 24 Participants Successfully Complete Treatment in Part a of Cmnd-100 Trial

THOMSON REUTERS
·
Jul 30

Clearmind Medicine completes Part A of CMND-100 trial

TIPRANKS
·
Jul 28

Clearmind Medicine Successfully Completes Part a of Its FDA Regulated Phase I/Ii Trial

Reuters
·
Jul 28

Clearmind Completes Part a Dosing in Phase I/II Cmnd-100 Trial for Alcohol Use Disorder

Reuters
·
Jul 28

Clearmind Targets Hong Kong Patent Protection to Support PTSD Drug Development Push

Reuters
·
Jul 20

Clearmind Medicine - Files Hong Kong Patent Application for Psychedelic Compounds Targeting Ptsd

THOMSON REUTERS
·
Jul 20

Clearmind reports positive retention results for intranasal formulation of MEAI

TIPRANKS
·
Jul 16

Clearmind Medicine Releases Update on Intranasal MEAI Formulation Retention Study

Reuters
·
Jul 16

Clearmind Medicine - Results Validate Clearmind Nasal Drug-delivery Platform for Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of Its Psychedelic-based Neuroplastogen Meai

THOMSON REUTERS
·
Jul 16

Clearmind Medicine Posts Update on Cmnd-100 First-in-human Trial Webinar Insights

Reuters
·
Jul 13

Clearmind Medicine submits response to HHS request for information

TIPRANKS
·
Jul 10

Clearmind Medicine Responds to the U.S. Administration’s Rfi for Addiction Treatment Innovations as Part of the Great American Recovery Initiative

THOMSON REUTERS
·
Jul 10

Clearmind Reports Successful Formulation Study for Intranasal MEAI Delivery in Alcohol Use Disorder Program

Reuters
·
Jul 08

Clearmind Medicine Issues Press Release Update

Reuters
·
Jul 07

Clearmind Medicine Wins New US Patent for Binge Behavior Regulators

Reuters
·
Jun 29

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 22

Clearmind Medicine - to Initiate Next Stage of Clinical Program for Alcohol Use Disorder

THOMSON REUTERS
·
Jun 22